Peptide therapies should be prescribed and supervised by a licensed medical provider
Anti-DPP4 vaccine has been proven effective in mice to control glucose homeostasis and might represent another potential approach
While human studies remain scarce, emerging in vitro models simulating human gut conditions reveal variable microbiota responses to MPs, ranging from dysbiosis and inflammatory metabolite production to probiotic enrichment and metabolic adaptation (Fournier et al., 2023
References: TripleHormoneReceptor Agonist Retatrutide for Obesity A Phase 2 Trial, Jastreboff et al., 2023 NEJM, Retatrutide, a GIP, GLP1 and glucagon receptor agonist, for people with type 2 diabetes, Rosenstock et al., 2023 The Lancet, Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis, Giblin et al., 2025 Diabetes, Obesity and Metabolism, Retatrutide is currently an investigational compound undergoing clinical research and has not yet been approved as a medicine by regulatory authorities.Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country